公开(公告)号：US20230190751A1

公开(公告)日：2023-06-22

申请号：US17820613

申请日：2022-08-18

Applicant: Novartis AG

Inventor： Dirk BEHNKE ,  Frada BERENSHTEYN ,  Xueshi HAO ,  Timothy Z. HOFFMAN ,  Qihui JIN ,  Arnaud LACOSTE ,  Cameron LEE ,  Jun LIU ,  Yahu A. LIU ,  Juergen Klaus MAIBAUM ,  Tingting MO ,  Jianfeng PAN ,  Xin QU ,  Jan TCHORZ ,  Yun Feng XIE ,  Shanshan YAN ,  Yefen ZOU

IPC: A61K31/519 ,  C07D487/04 ,  C12N5/079 ,  C07D519/00 ,  A61P17/02 ,  A61K9/00 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/506

CPC classification number: A61K31/519 ,  C07D487/04 ,  C12N5/0621 ,  C07D519/00 ,  A61P17/02 ,  A61K9/0048 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/506 ,  A61K35/30

Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein.




The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

公开(公告)号：US20180344738A1

公开(公告)日：2018-12-06

申请号：US15963816

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Dirk BEHNKE ,  Frada BERENSHTEYN ,  Xueshi HAO ,  Timothy HOFFMAN ,  Qihui JIN ,  Arnaud LACOSTE ,  Cameron LEE ,  Jun LIU ,  Yahu LIU ,  Juergen Klaus MAIBAUM ,  Tingting MO ,  Jianfeng PAN ,  Xin QU ,  Jan TCHORZ ,  Yun Feng XIE ,  Shanshan YAN ,  Yefen ZOU

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/4375 ,  A61K31/506 ,  A61K31/47

CPC classification number: C07D519/00 ,  A61K35/30 ,  A61P17/02 ,  C07D487/04 ,  C12N5/0621

Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

公开(公告)号：US20190203230A1

公开(公告)日：2019-07-04

申请号：US16331967

申请日：2017-09-28

Applicant: NOVARTIS AG

Inventor： Fabio FACHIN ,  Michael FIORINO ,  Cameron LEE ,  Yi YANG ,  Jonathan YEN

IPC: C12N15/90 ,  C12N15/87

CPC classification number: C12N15/907 ,  C12N15/102 ,  C12N15/87 ,  C12N2310/20 ,  C12N2800/80

Abstract: In one aspect, a method of processing a cell is disclosed, which includes passing a cell through a pore of a membrane comprising a plurality of pores while exposing the cell to an agent so as to cause a change in the cell, thereby allowing said agent to enter the cell, where each of said pores extends from an input opening to an output opening and has at least one cross-sectional dimension, and in many embodiments a maximum cross-sectional dimension, less than a diameter of said cell. For example, at least one cross-sectional dimension of the pore, and in many embodiment the maximum cross-sectional dimension of the pore, can be less than about 40 microns, or less than about 30 microns, or less than about 20 microns, or less than about 15 microns, or less than about 10 microns.